Alnylam Pharmaceuticals- RNAi technology
Alnylam have a long history of developing the therapeutic potential of RNAi technology. In particular their platform is focused on mRNAs expressed in hepatocytes, utilizing a specific hepatocyte interaction for drug targeting. This seminar will outline their approach and product pipeline, with a view to discussing potential collaboration.
This seminar is for anyone with a broad interest in RNAi technology.
Date:
10 May 2017, 10:00
Venue:
Richard Doll Building, Old Road Campus OX3 7LF
Venue Details:
Lecture Hall
Speakers:
Patrick Haslam (Alnylam),
David Erbe (Alnylam)
Organising department:
Medical Sciences Office
Organisers:
Oliver Voss (Business Development Medical Sciences),
Martin Kerr (Business Development Medical Sciences)
Organiser contact email address:
martin.kerr@medsci.ox.ac.uk
Host:
Medical Sciences Division Business Partnerships Office (University of Oxford)
Topics:
Booking required?:
Not required
Cost:
FREE
Audience:
Members of the University only
Editor:
Martin Kerr
